The FDA announced the approval of the Dexcom Stelo Glucose Biosensor System, the first over-the-counter continuous glucose monitor for individuals 18 years and older not on insulin. This device allows users to monitor glucose levels without a health care provider’s involvement, emphasizing health equity for all patients. The system uses a wearable sensor and smartphone app to provide continuous glucose measurements every 15 minutes. However, it’s important to note that the system is not suitable for individuals with problematic hypoglycemia. Despite some adverse events reported in clinical studies, the FDA continues to push for innovation that promotes health equity and wellness at home.
https://www.fda.gov/news-events/press-announcements/fda-clears-first-over-counter-continuous-glucose-monitor